Bausch Health Companies Inc. Revenue in 2024

Bausch Health Companies Inc. reported $8.9B in revenue for fiscal year 2024. This represents a growth of 2.3% compared to the 2023 figure of $8.7B.

Revenue of $8.9 billion in FY2024 shows a recovery from the post-Valeant restructuring period, when assets were sold to pay down debt and revenue fell from peak levels. The $15.5 billion debt load is the defining financial constraint — every operating decision, every capital allocation choice, every acquisition or divestiture is evaluated through the lens of debt service capacity. The Xifaxan franchise's $3.1 billion in FY2024 revenue at 35% of total corporate revenue makes the company essentially a one-drug business with supporting operations in dermatology and neurology. Shire, the rare disease firm that AbbVie acquired, faced a similar concentration problem with its ADHD medications. The Xifaxan patent, combined with the complexity of manufacturing the branded formulation, has so far held generic competition at bay — but the defense has a finite duration. Free cash flow of $2.1 billion in FY2024 and an operating income of $1.8 billion against $8.9 billion in revenue reflect a 72% gross margin that demonstrates the pricing power of specialty pharmaceutical products with limited competition. The R&D investment of $1.2 billion in FY2024, representing 13.5% of total revenue, funds over 30 clinical projects — a significant increase from the Valeant era, when R&D was treated as optional overhead. Market capitalization of approximately $2.5 billion against $8.9 billion in revenue and $2.1 billion in free cash flow is a structure that prices equity holders as residual claimants who will receive value only after the $15.5 billion in debt obligations are satisfied. The company is a leveraged buyout in public market form — a structure that rewards equity dramatically if the debt is managed down, and wipes equity entirely if it isn't.